DENTSPLY SIRONA Inc. (NASDAQ:XRAY) has earned a consensus rating of “Buy” from the fifteen brokerages that are presently covering the company, Marketbeat.com reports. Two research analysts have rated the stock with a sell rating, three have given a hold rating and nine have issued a buy rating on the company. The average 12 month price target among brokerages that have covered the stock in the last year is $67.09.

Several equities research analysts recently issued reports on XRAY shares. Credit Suisse Group reiterated an “outperform” rating and issued a $75.00 target price (up from $67.00) on shares of DENTSPLY SIRONA in a research note on Thursday, July 13th. BidaskClub downgraded shares of DENTSPLY SIRONA from a “hold” rating to a “sell” rating in a research note on Friday, July 28th. Zacks Investment Research upgraded shares of DENTSPLY SIRONA from a “sell” rating to a “hold” rating and set a $71.00 target price for the company in a research note on Tuesday, May 2nd. Stifel Nicolaus reissued a “buy” rating and issued a $66.00 price target (down from $70.00) on shares of DENTSPLY SIRONA in a report on Thursday. Finally, UBS AG reissued a “neutral” rating and issued a $59.00 price target (down from $62.00) on shares of DENTSPLY SIRONA in a report on Thursday.

DENTSPLY SIRONA (NASDAQ XRAY) traded down 0.31% during trading on Friday, hitting $55.33. The stock had a trading volume of 3,566,593 shares. The company’s market capitalization is $12.70 billion. DENTSPLY SIRONA has a 12-month low of $54.49 and a 12-month high of $65.68. The stock has a 50 day moving average price of $62.91 and a 200 day moving average price of $62.30.

DENTSPLY SIRONA (NASDAQ:XRAY) last issued its earnings results on Wednesday, August 9th. The medical instruments supplier reported $0.65 earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.65. DENTSPLY SIRONA had a negative net margin of 20.57% and a positive return on equity of 7.24%. The business had revenue of $992.70 million during the quarter, compared to the consensus estimate of $1 billion. During the same period last year, the business posted $0.76 EPS. DENTSPLY SIRONA’s revenue was down 2.9% on a year-over-year basis. Equities research analysts forecast that DENTSPLY SIRONA will post $2.73 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 13th. Investors of record on Friday, September 29th will be paid a $0.0875 dividend. The ex-dividend date of this dividend is Thursday, September 28th. This represents a $0.35 dividend on an annualized basis and a yield of 0.63%. DENTSPLY SIRONA’s dividend payout ratio (DPR) is -10.09%.

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Alps Advisors Inc. raised its stake in shares of DENTSPLY SIRONA by 0.3% in the second quarter. Alps Advisors Inc. now owns 7,523 shares of the medical instruments supplier’s stock worth $488,000 after buying an additional 20 shares in the last quarter. Ropes Wealth Advisors LLC raised its stake in shares of DENTSPLY SIRONA by 0.3% in the first quarter. Ropes Wealth Advisors LLC now owns 9,003 shares of the medical instruments supplier’s stock worth $562,000 after buying an additional 29 shares in the last quarter. Wetherby Asset Management Inc. raised its stake in shares of DENTSPLY SIRONA by 0.6% in the second quarter. Wetherby Asset Management Inc. now owns 5,004 shares of the medical instruments supplier’s stock worth $324,000 after buying an additional 30 shares in the last quarter. HighTower Advisors LLC raised its stake in shares of DENTSPLY SIRONA by 0.6% in the first quarter. HighTower Advisors LLC now owns 6,823 shares of the medical instruments supplier’s stock worth $424,000 after buying an additional 39 shares in the last quarter. Finally, BRYN MAWR TRUST Co raised its stake in shares of DENTSPLY SIRONA by 0.5% in the second quarter. BRYN MAWR TRUST Co now owns 12,064 shares of the medical instruments supplier’s stock worth $782,000 after buying an additional 65 shares in the last quarter. 95.17% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: This piece of content was published by Daily Political and is the property of of Daily Political. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of United States and international copyright and trademark law. The original version of this piece of content can be accessed at https://www.dailypolitical.com/2017/08/12/dentsply-sirona-inc-nasdaqxray-receives-consensus-recommendation-of-buy-from-analysts.html.

DENTSPLY SIRONA Company Profile

DENTSPLY SIRONA Inc is a manufacturer of professional dental products and technologies. The Company develops, manufactures, and markets solutions offering, including dental and oral health products, as well as other consumable medical devices. It operates through two segments: Dental and Healthcare Consumables, and Technologies.

Analyst Recommendations for DENTSPLY SIRONA (NASDAQ:XRAY)

Receive News & Ratings for DENTSPLY SIRONA Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DENTSPLY SIRONA Inc. and related companies with MarketBeat.com's FREE daily email newsletter.